Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Parecoxib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 11/20 | 0.98 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.98 |
| ▸ | MT-CO2 | P00403 | 3/20 | 0.71 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.60 |
| ▸ | CA12 | O43570 | 1/20 | 0.60 |
| ▸ | CA1 | P00915 | 1/20 | 0.60 |
| ▸ | CA2 | P00918 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | CA3 | P07451 | 1/20 | 0.60 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.60 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.60 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.60 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.60 |
| ▸ | CA4 | P22748 | 1/20 | 0.60 |
| ▸ | CA6 | P23280 | 1/20 | 0.60 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.60 |
| ▸ | PDE4A | P27815 | 1/20 | 0.60 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Parecoxib SCHEMBL28381051 | 1.00 | PTGS2 (0.98) | PTGS2NR4A2MT-CO2PTGS1CA12 | |
| SCHEMBL28646416 | 0.99 | PTGS2 (1.00) | PTGS2NR4A2MT-CO2PTGS1CA12 | |
| Parecoxib SCHEMBL29561416 | 0.99 | PTGS2 (1.00) | PTGS2NR4A2MT-CO2PTGS1CA12 | |
| Parecoxib SCHEMBL9529 | 0.99 | PTGS2 (1.00) | PTGS2NR4A2MT-CO2PTGS1CA12 | |
| Parecoxib SCHEMBL5709079 | 0.98 | PTGS2 (0.98) | PTGS2NR4A2MT-CO2PTGS1CA12 | |
| Parecoxib SCHEMBL28339255 | 0.97 | PTGS2 (0.96) | PTGS2NR4A2MT-CO2PTGS1CA12 | |
| Parecoxib SCHEMBL28086681 | 0.94 | PTGS2 (0.90) | PTGS2NR4A2MT-CO2PTGS1CA12 | |
| SCHEMBL13772645 | 0.91 | PTGS2 (0.85) | PTGS2NR4A2MT-CO2PTGS1CA12 | |
| SCHEMBL12546410 | 0.91 | PTGS2 (0.85) | PTGS2NR4A2MT-CO2PTGS1CA12 | |
| SCHEMBL5071003 | 0.90 | PTGS2 (0.84) | PTGS2NR4A2MT-CO2PTGS1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1764 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120022235-A | Lactic acid-containing composition, injection containing composition, and preparation method and application of composition | 复旦大学 | 2025-05-23 | — | — | CN | claimed |
| CN-119506908-A | Synthesis method of parecoxib sodium intermediate | 四川轻化工大学 | 2025-02-25 | — | — | CN | claimed |
| CN-222286643-U | A filter equipment for filtering impurity in parecoxib sodium synthesis process | 成都晶富医药科技有限公司 | 2025-01-03 | — | — | CN | claimed |
| CN-118831060-A | Parecoxib sodium freeze-dried preparation for injection and preparation method thereof | 成都晶富医药科技有限公司 | 2024-10-25 | — | — | CN | claimed |
| CN-118425359-A | Parafaxib sodium raw material and method for measuring propionic acid content in preparation thereof | 成都晶富医药科技有限公司 | 2024-08-02 | — | — | CN | claimed |
| CN-117243901-A | Development of parecoxib sodium freeze-dried injection for injection | 杭州和康药业有限公司 | 2023-12-19 | — | — | CN | claimed |
| US-11826354-B2 | Pharmaceutical compositions comprising meloxicam | AXSOME THERAPEUTICS, INC. (US) | 2023-11-28 | — | — | US | claimed |
| WO-2023214433-A1 | STABLE PARENTERAL COMPOSITIONS OF PARECOXIB | INVENTIA HEALTHCARE LIMITED (IN) | 2023-11-09 | — | — | WO | claimed |
| CN-116421569-B | Parafaxib sodium pharmaceutical composition for injection and preparation method thereof | 四川尚锐生物医药有限公司 | 2023-09-05 | — | — | CN | claimed |
| EP-2796112-B2 | Degradable implantable medical devices | ELIXIR MEDICAL CORP (US) | 2023-08-09 | — | — | EP | claimed |
| US-20030232871-A1 | Crystalline parecoxib sodium | PHARMACIA CORPORATION | 2003-12-18 | — | — | US | claimed |
| WO-2003101380-A2 | AMYOTROPHIC LATERAL SCLEROSIS TREATMENT WITH CYCLOOXYGENASE-2 INHIBITORS | PHARMACIA CORPORATION (US) | 2003-12-11 | — | — | WO | claimed |
| WO-2003101441-A1 | MONOTHERAPY FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS WITH CYCLOOXYGENASE-2 (COX 2) INHIBITOR(S) | PHARMACIA CORPORATION (US) | 2003-12-11 | — | — | WO | claimed |
| WO-2003092691-A1 | COMBINATION OF CYCLOOXYGENASE-2 INHIBITORS AND THALIDOMIDE FOR THE TREATMENT OF NEOPLASIA | PHARMACIA COPORATION (US) | 2003-11-13 | — | — | WO | claimed |
| WO-2003088959-A2 | TREATMENT OF PARKINSON'S DISEASE WITH CYCLOOXYGENASE-2 (COX 2) INHIBITOR(S) | PHARMACIA CORPORATION (US) | 2003-10-30 | — | — | WO | claimed |
| WO-2003088958-A2 | COMBINATIONS OF COX-2 INHIBITORS AND OTHER AGENTS FOR THE TREATMENT OF PARKINSON’S DISEASE | PHARMACIA CORPORATION (US) | 2003-10-30 | — | — | WO | claimed |
| WO-2003078408-A1 | CRYSTALLINE PARECOXIB SODIUM | PHARMACIA CORPORATION (US) | 2003-09-25 | — | — | WO | claimed |
| US-20030078266-A1 | Reconstitutable parenteral composition | PHARMACIA LLC | 2003-04-24 | — | — | US | claimed |
| US-20030013739-A1 | Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia | PHARMACIA CORPORATION | 2003-01-16 | — | — | US | claimed |
| WO-2002080912-A1 | RECONSTITUTABLE PARENTERAL COMPOSITION CONTAINING A COX-2 INHIBITOR | PHARMACIA CORPORATION (US) | 2002-10-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232871-A1 | Crystalline parecoxib sodium | PYGL, LPXN, PYGM | PTGS2 82/4885NR4A2 4649/4885MT-CO2 3747/4885 |
| US-20030013739-A1 | Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia | PTGS2, PTGES2, PTGS1 | PTGS2 1/4885NR4A2 1798/4885MT-CO2 1289/4885 |
| US-11826354-B2 | Pharmaceutical compositions comprising meloxicam | CA9, CALCA, MC3R | PTGS2 492/4885NR4A2 1520/4885MT-CO2 819/4885 |
| US-20030078266-A1 | Reconstitutable parenteral composition | PTGES2, PTGS2, PTGER2 | PTGS2 2/4885NR4A2 4619/4885MT-CO2 1362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.